Developer docs
API playgroundTry for free, no card

Search company profiles

Good Start Genetics

Full company profile

uuid0007bcp

Namestring
Good Start Genetics
Websiteurl
goodstartgenetics.com
Company typeenum
Private
Founded yearint
2008
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
genetic testing services, molecular diagnostics, NGS-based testing, hereditary cancer screening, preimplantation genetic testing
Industry5 codes
1Molecular & Genetic Testing (PCR/NGS/qPCR)
CodeHLAGADAFPrimaryYes
2Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
CodeHLAAALADPrimaryNo
3Genomics & Next-Generation Sequencing (NGS) Services
CodeHLAGANAAPrimaryNo
4Molecular Diagnostics & Genomics Laboratories
CodeHLAFAMAEPrimaryNo
5Genomic Profiling & Sequencing-Based Precision Medicine
CodeHLAAANAAPrimaryNo
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Genetic Testing Services
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Good Start Genetics is a molecular genetic information company that operates a proprietary Next-Generation Sequencing (NGS) platform to deliver clinical genetic testing services. The company provides comprehensive multi-gene panel tests across oncology, women's health, pediatrics, cardiology, neurology, hereditary cancer, and rare diseases, serving healthcare providers with diagnostic, prognostic, and treatment-decision genetic insights.

Differentiator
Functional benefit
Problem solved
Product and service9 records
1Invitae Multi-Cancer Panel
CategoryHereditary Cancer Testing
Description

71-gene multi-cancer panel test providing genetic information that can inform treatment and clinical trial opportunities for oncology patients.

2Invitae Common Hereditary Cancers Panel
CategoryHereditary Cancer Testing
Description

49-gene panel targeting common hereditary cancers, designed for hereditary cancer screening and risk assessment.

3Invitae Hereditary Breast Cancer STAT Panel
CategoryHereditary Cancer Testing
Description

Up to 9-gene STAT (rapid turnaround) hereditary breast cancer panel for time-sensitive clinical decision-making.

4Invitae Hereditary Colorectal Cancer Panel
CategoryHereditary Cancer Testing
Description

Up to 33-gene hereditary colorectal cancer panel for risk assessment and treatment personalization.

5Cardiology Genetic Test Panels
CategoryCardiology Genetic Testing
Description

Genetic test panels for cardiovascular conditions, providing insights to improve diagnosis, prognosis, and patient care.

6Pediatric & Rare Disease Genetic Test Panels
CategoryPediatric & Rare Disease Testing
Description

Genetic information for patients with pediatric onset of rare diseases to inform prognosis, treatments, and next steps.

7Neurology Genetic Test Panels
CategoryNeurology Genetic Testing
Description

Genetic test panels for neurological disorders to support diagnosis and treatment decisions.

8Genetic Risk Assessment Test Panels
CategoryGenetic Risk Assessment
Description

Comprehensive genetic risk assessment panels to add to patients' toolkit during routine care.

9Labcorp Plasma Detect ID MRD
CategoryOncology Testing
Description

MRD (minimal residual disease) detection test using plasma sample analysis.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Invitae
TypeDirect peer
Description

Invitae is Good Start Genetics' parent platform within Labcorp and operates an essentially overlapping NGS-based multi-specialty genetic testing menu (oncology, reproductive, rare disease, cardiology, neurology). They are direct peers; the relationship is now corporate rather than purely competitive.

2Natera
TypeDirect peer
Description

Natera is a molecular diagnostics company offering NGS-based reproductive health testing (PGT, NIPT, carrier screening) and oncology/solid tumor MRD assays. Highly comparable to GSG's reproductive and oncology genetic testing franchises.

3Myriad Genetics
TypeDirect peer
Description

Myriad is an established genetic testing company with hereditary cancer, women's health, and pharmacogenomic panels, competing directly with GSG/Invitae in oncology and reproductive health.

4Ambry Genetics
TypeDirect peer
Description

Ambry (acquired by Koninklijke Philips) offers NGS-based hereditary cancer, reproductive, and rare disease testing — a near-direct product overlap with GSG's multi-specialty menu.

5Color Health
TypeDirect peer
Description

Color provides hereditary cancer, cardiovascular, and pharmacogenomic NGS testing with a focus on population-scale programs and employer/payer channels, competing with GSG on price and access.

6Sema4
TypeDirect peer
Description

Sema4 offers reproductive, hereditary cancer, and rare-disease NGS testing, overlapping GSG's reproductive and rare-disease segments with similar provider-direct distribution.

7GeneDx
TypeDirect peer
Description

GeneDx focuses on rare disease and pediatric exome/genome testing, a strong comparable to GSG's pediatric and rare-disease genetics business.

8Fulgent Genetics
TypeDirect peer
Description

Fulgent offers NGS panels across reproductive, oncology, and rare disease as well as whole-exome sequencing, with comparable technology and provider-direct channels.

9Igenomix
TypeDirect peer
Description

Igenomix is a global reproductive genetics lab specializing in PGT, NIPT, carrier screening, and reproductive endocrinology testing — closely aligned with Good Start Genetics' original embryo-screening focus.

10Labcorp (Diagnostics)
TypeBroad incumbent
Description

Labcorp is GSG's ultimate parent and a broad incumbent offering routine clinical lab, women's health, and oncology diagnostics; it competes with GSG indirectly via its broader women's health and hereditary cancer offerings while also providing infrastructure leverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Good Start Genetics

Genetic Testing Servicesgoodstartgenetics.com

Good Start Genetics firmographics

Firmographics
Name
Good Start Genetics
Website
https://goodstartgenetics.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Good Start Genetics industry classification

Industry
Product category
Genetic Testing Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro primary industry
Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)
akta.pro secondary industries
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

Keywords

  • Genetic testing services
  • Molecular diagnostics
  • NGS-based testing
  • Hereditary cancer screening
  • Preimplantation genetic testing

Where Good Start Genetics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Good Start Genetics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels4 records

Good Start Genetics product offering

Product offering

Core offering

Good Start Genetics is a molecular genetic information company that operates a proprietary Next-Generation Sequencing (NGS) platform to deliver clinical genetic testing services. The company provides comprehensive multi-gene panel tests across oncology, women's health, pediatrics, cardiology, neurology, hereditary cancer, and rare diseases, serving healthcare providers with diagnostic, prognostic, and treatment-decision genetic insights.

Differentiator

Problem solved

Functional benefit

Products and services

  • Invitae Multi-Cancer Panel 71-gene multi-cancer panel test providing genetic information that can inform treatment and clinical trial opportunities for oncology patients.
  • Invitae Common Hereditary Cancers Panel 49-gene panel targeting common hereditary cancers, designed for hereditary cancer screening and risk assessment.
  • Invitae Hereditary Breast Cancer STAT Panel Up to 9-gene STAT (rapid turnaround) hereditary breast cancer panel for time-sensitive clinical decision-making.
  • Invitae Hereditary Colorectal Cancer Panel Up to 33-gene hereditary colorectal cancer panel for risk assessment and treatment personalization.
  • Cardiology Genetic Test Panels Genetic test panels for cardiovascular conditions, providing insights to improve diagnosis, prognosis, and patient care.
  • Pediatric & Rare Disease Genetic Test Panels Genetic information for patients with pediatric onset of rare diseases to inform prognosis, treatments, and next steps.
  • Neurology Genetic Test Panels Genetic test panels for neurological disorders to support diagnosis and treatment decisions.
  • Genetic Risk Assessment Test Panels Comprehensive genetic risk assessment panels to add to patients' toolkit during routine care.
  • Labcorp Plasma Detect ID MRD MRD (minimal residual disease) detection test using plasma sample analysis.

Companies that use Good Start Genetics

Customer profile

Segments1 record

Ideal customer profiles1 record

Good Start Genetics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Good Start Genetics partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights5 records

Good Start Genetics competitors and assessment

Company assessment

Direct peers

  • Invitae: Invitae is Good Start Genetics' parent platform within Labcorp and operates an essentially overlapping NGS-based multi-specialty genetic testing menu (oncology, reproductive, rare disease, cardiology, neurology). They are direct peers; the relationship is now corporate rather than purely competitive.
  • Natera: Natera is a molecular diagnostics company offering NGS-based reproductive health testing (PGT, NIPT, carrier screening) and oncology/solid tumor MRD assays. Highly comparable to GSG's reproductive and oncology genetic testing franchises.
  • Myriad Genetics: Myriad is an established genetic testing company with hereditary cancer, women's health, and pharmacogenomic panels, competing directly with GSG/Invitae in oncology and reproductive health.
  • Ambry Genetics: Ambry (acquired by Koninklijke Philips) offers NGS-based hereditary cancer, reproductive, and rare disease testing — a near-direct product overlap with GSG's multi-specialty menu.
  • Color Health: Color provides hereditary cancer, cardiovascular, and pharmacogenomic NGS testing with a focus on population-scale programs and employer/payer channels, competing with GSG on price and access.
  • Sema4: Sema4 offers reproductive, hereditary cancer, and rare-disease NGS testing, overlapping GSG's reproductive and rare-disease segments with similar provider-direct distribution.
  • GeneDx: GeneDx focuses on rare disease and pediatric exome/genome testing, a strong comparable to GSG's pediatric and rare-disease genetics business.
  • Fulgent Genetics: Fulgent offers NGS panels across reproductive, oncology, and rare disease as well as whole-exome sequencing, with comparable technology and provider-direct channels.
  • Igenomix: Igenomix is a global reproductive genetics lab specializing in PGT, NIPT, carrier screening, and reproductive endocrinology testing — closely aligned with Good Start Genetics' original embryo-screening focus.

Broad incumbents

  • Labcorp (Diagnostics): Labcorp is GSG's ultimate parent and a broad incumbent offering routine clinical lab, women's health, and oncology diagnostics; it competes with GSG indirectly via its broader women's health and hereditary cancer offerings while also providing infrastructure leverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Good Start Genetics social profiles

Digital presence

Good Start Genetics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Good Start Genetics leadership team

Management profile

Number of profiles

Good Start Genetics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Good Start Genetics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Good Start Genetics

What does Good Start Genetics do?

Good Start Genetics is a molecular genetic information company that operates a proprietary Next-Generation Sequencing (NGS) platform to deliver clinical genetic testing services. The company provides comprehensive multi-gene panel tests across oncology, women's health, pediatrics, cardiology, neurology, hereditary cancer, and rare diseases, serving healthcare providers with diagnostic, prognostic, and treatment-decision genetic insights.

When was Good Start Genetics founded?

Good Start Genetics was founded in 2008. It employs 101 to 250 people.

Where is Good Start Genetics based?

Good Start Genetics is headquartered in Cambridge, United States, in the North America region.

Who are Good Start Genetics's main competitors?

Direct peers on record are Invitae, Natera, Myriad Genetics, Ambry Genetics, Color Health, Sema4, GeneDx, Fulgent Genetics and Igenomix. Labcorp (Diagnostics) is listed as a broad incumbent.

Does Good Start Genetics have an API?

No public API is recorded for Good Start Genetics.

What industry is Good Start Genetics in?

Good Start Genetics's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireInvitae Acquiring Good Start Genetics and CombiMatrix, Adding Comprehensive Reproductive Health Capabilities to Serve Every Stage of LifeInvitae Corporation has announced two acquisitions: Good Start Genetics, a company specializing in preimplantation and carrier screening, and CombiMatrix, known for prenatal diagnosis and miscarriage analysis. These acquisitions aim to establish Invitae as a leading provider of genetic information services across all stages of life, involving a significant stock and cash consideration totaling approximately $51.3 million. The acquisitions are expected to close in August and the fourth quarter of 2017, respectively, subject to closing conditions.PR NewswireSafeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae CorporationGood Start Genetics, a partner company of Safeguard Scientifics, has signed a definitive agreement to be acquired by Invitae Corporation, with the transaction expected to close in early August 2017. Safeguard will receive approximately $5.1 million in Invitae common stock, consisting of $3.8 million in initial consideration and $1.3 million held in escrow for up to 13 months. Safeguard's CEO described the outcome as a "significant shortfall" relative to return expectations, though he noted that a larger, more financially capable enterprise was necessary to advance Good Start's genetic testing vision.PR NewswireLeading Family Genomics Company Good Start Genetics Expands Payor Relationships to More than 130 Million Covered LivesGood Start Genetics, a Cambridge-based family genomics company, announced it has surpassed 130 million covered lives through its payor relationships, with the most recent addition being Blue Cross Blue Shield of Texas. The milestone reflects strong payor acceptance driven by the company's genetic testing quality, clinical programs, and published cost-effectiveness studies. The company noted that this achievement coincides with ACOG's updated medical guidelines recommending expanded disorder screening, which aligns with Good Start Genetics' existing testing offerings.PR NewswireGood Start Genetics and Genome Medical Announce Partnership to Provide Genetic Counseling to Couples Undergoing Carrier TestingGood Start Genetics and Genome Medical announced a partnership to provide genetic counseling to couples undergoing carrier testing through Good Start's VeriYou screening platform. The collaboration integrates Genome Medical's certified genetic counselors into Good Start's physician-mediated carrier screening offering, which tests for cystic fibrosis and spinal muscular atrophy—the two most common inherited disorders in children—targeting the 62 million women that medical societies suggest should be screened. The partnership aims to help ensure patients and physicians fully understand test results, positive or negative, with high-quality, affordable genetic counseling as genomics becomes increasingly integrated within healthcare.PR NewswireGood Start Genetics Brings First Next-Generation Sequencing (NGS) Test to Amazon Enabling Broad Access to Carrier Screening for Couples Starting a FamilyGood Start Genetics announced the launch of its VeriYou saliva-based NGS carrier screening test on Amazon, making it the first genetic testing company to establish a direct Amazon relationship for this type of product. The test screens for cystic fibrosis and spinal muscular atrophy at $149, targeting couples planning families with physician-mediated testing and genetic counseling access. The company aims to broaden adoption of carrier screening by leveraging Amazon's marketplace reach and analytics capabilities to connect with prospective parents at the right life stage.PR NewswireGood Start Genetics to Present New Scientific Findings at The American Society of Human Genetics ConferenceGood Start Genetics announced plans to present data from three scientific studies at the American Society of Human Genetics annual meeting, covering carrier testing for hemoglobin variants, spinal muscular atrophy screening, and validation of their preimplantation genetic screening test. One of the studies, on segmental aneuploidy detection using next-generation sequencing, was selected as a Reviewers' Choice Abstract, placing it in the top 10 percent of abstracts. The presentations will be delivered by the company's VP of Research and Development and principal scientists.PR NewswireGood Start Genetics to Present New In Vitro Fertilization Scientific Findings at the American Society of Reproductive Medicine ConferenceGood Start Genetics announced it will present data from three scientific studies on its EmbryVu preimplantation genetic screening test at the American Society for Reproductive Medicine annual meeting. The studies validate the test's ability to detect both whole chromosome and segmental aneuploidies using the company's next-generation sequencing platform, which was developed with technology exclusively licensed from Johns Hopkins University. The company highlighted that its proprietary platform enables it to offer EmbryVu at considerably lower prices than other PGS tests currently available, potentially expanding patient access to high-quality genetic screening.PR NewswireGood Start Genetics Announces New Tier of Offerings Making Genetic Testing More Accessible for Couples Planning a FamilyGood Start Genetics launched VeriYou, a saliva-based genetic screening test for cystic fibrosis and spinal muscular atrophy, on October 13, 2016 in Cambridge, Massachusetts. The test targets the one in 19 people who carry CF or SMA mutations that could be passed to offspring, addressing a gap highlighted by ACOG and ACMG recommendations that many couples remain untested due to lack of awareness or affordability. The company is expanding its portfolio into two tiers to broaden access through fertility clinic relationships and physician-mediated channels nationwide.PR NewswireWith Pediatric Scientific Advisory Board, Good Start Genetics Plots a Course to Expanded Markets in Family CareGood Start Genetics announced the formation of a pediatric scientific advisory board as part of its strategy to expand into broader genetic testing for families, from preconception through early childhood. The advisory board includes leaders from Verily, Brigham and Women's Hospital, and Children's Hospital of Philadelphia. The company, which was the first to bring next-generation sequencing to reproductive health, aims to leverage its existing 100,000+ patient customer base to extend its platform into new family genetics markets.GlobeNewswireSafeguard Scientifics Updates Agenda for Investor Day 2014Safeguard Scientifics will host its 8th Annual Investor Day on October 15, 2014, at the New York Stock Exchange. The agenda includes presentations from Safeguard executives and partner companies such as Good Start Genetics, Spongecell, and Apprenda, with RSVPs due by October 10.